| Names | |
|---|---|
| Preferred IUPAC name | 2-aminobutanamide |
| Other names | DL-2-Aminobutyramide 2-Aminobutanamide 2-Aminobutyramide Butanamide, 2-amino- DL-2-Aminobutyric acid amide |
| Pronunciation | /diː ɛl tuː əˌmiːnoʊ bjuːˈtɪrəmaɪd/ |
| Identifiers | |
| CAS Number | 5988-51-2 |
| Beilstein Reference | 1859281 |
| ChEBI | CHEBI:16643 |
| ChEMBL | CHEMBL1929953 |
| ChemSpider | 127042 |
| DrugBank | DB08394 |
| ECHA InfoCard | 100.126.282 |
| EC Number | 214-806-0 |
| Gmelin Reference | 65737 |
| KEGG | C02957 |
| MeSH | D000638 |
| PubChem CID | 21112365 |
| RTECS number | AB8575000 |
| UNII | 6A5U0ZH6YW |
| UN number | Not assigned |
| CompTox Dashboard (EPA) | DTXSID7063530 |
| Properties | |
| Chemical formula | C4H10N2O |
| Molar mass | 102.14 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.08 g/cm3 |
| Solubility in water | soluble |
| log P | -2.18 |
| Acidity (pKa) | 10.1 |
| Basicity (pKb) | 6.57 |
| Magnetic susceptibility (χ) | -41.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.488 |
| Dipole moment | 5.99 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | “203.5 J·mol⁻¹·K⁻¹” |
| Std enthalpy of formation (ΔfH⦵298) | -172.6 kJ/mol |
| Hazards | |
| Main hazards | Harmful if swallowed, causes skin and eye irritation |
| GHS labelling | GHS02, GHS07 |
| Pictograms | ["GHS07"] |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection. IF ON SKIN: Wash with plenty of water. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | Flash point: >110°C |
| Lethal dose or concentration | LD50 Oral Rat 2000 mg/kg |
| LD50 (median dose) | LD50: 1470 mg/kg (Rat, oral) |
| NIOSH | MWG130 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 10 mg/ml |
| IDLH (Immediate danger) | NIOSH does not have a published IDLH value for DL-2-Aminobutyramide. |
| Related compounds | |
| Related compounds | 2-Aminobutyric acid L-2-Aminobutyric acid DL-2-Aminobutanol DL-2-Aminobutyronitrile DL-2-Aminobutyric acid hydrochloride |
| Product Name & IUPAC Name | DL-2-Aminobutyramide IUPAC: 2-Aminobutanamide |
|---|---|
| Chemical Formula | C4H10N2O |
| Synonyms & Trade Names | DL-2-Butanamide, 2-Aminobutanamide; Rac-2-Aminobutyramide; ±-2-Aminobutyramide |
| HS Code & Customs Classification | HS Code assignment varies according to intended end-use and local customs interpretation. Technically, most shipments fall under 2924 – “Carboxyamide-function compounds; amide-function compounds of carbonic acid”. For export, documentation aligns with standardized tariff schedules as determined by composition and concentration, with supplementary classification for pharmaceutical, intermediate, or research use depending on contract terms and region of entry. |
In actual production, DL-2-Aminobutyramide output hinges on both the raw material profile and the configuration of aminolysis or transamidation steps. Sourcing bulk precursor feeds requires ongoing assessment of supplier consistency and impurity histories—sulfur or phosgene-based contaminants from certain synthetic routes can persist and shift batch quality. For variants needed in pharmaceutical or food-intermediate supply chains, the selection of biobased or fully synthetic origins drives grade segmentation, with the final release criterion shifting according to regulatory and end-customer demand.
Batch consistency in quality control flows from tightly managing the chain of amination and dehydration, constantly adjusting in response to analytic feedback for any by-products, such as secondary amines or acyl impurities, especially during high-throughput lots. Purification regimes lean on solvent extraction, crystallization, or resin absorption, each suited for the scale and required residual impurity limits. Actual storage and downstream handling recommendations change depending on the presence and trace levels of volatile amines or residual solvents in the delivered grade.
For customs clearance and international trade, the main constraint comes from how customs agencies recognize the function—intermediate, active pharmaceutical ingredient precursor, or specialty chemical. Minor differences in end-use documentation can change the applied tariff or inclusion in dual-use listings. Documentation for each shipment must state the composition and intended application in line with true batch release sheets and quality certificates. Misclassification or missing technical data leads to border delays or denial of entry, particularly for regions strictly enforcing chemical and dual-use protocols.
Internal release of DL-2-Aminobutyramide from our facilities always ties back to in-process analytic results: we focus on amide purity, residual amination by-products, and moisture content. These properties are yield-sensitive to operational variations and can only be fully verified by validated, instrument-based methods on the finished lot. Spec limits are defined for each customer type or regulatory expectation; no universal test grid applies. Continuous improvement circles back each year to revalidate process control points, with iterative upgrades as regulatory tolerances, solvent recovery systems, or impurity monitoring advances.
Production batches of DL-2-Aminobutyramide typically yield a crystalline solid. Physical form and color shift according to purity and grade; industrial lots may exhibit minor color tint variations traceable to precursor origin and purification depth. Odor profile remains faint to none under controlled synthesis and drying; residual amine notes signal process deviation or elevated impurity levels. Melting and boiling points, along with flash point and density, can shift marginally based on lot-specific purity—data should be referenced from actual COA for each batch.
Long-term stability is achieved when stored in well-sealed packaging away from sources of moisture and air, especially for high-purity pharmaceutical grades. Reactive profile is sensitive to strong oxidizers and acids; exposure introduces potential decomposition risk not just to bulk stock but also to process intermediates.
DL-2-Aminobutyramide dissolves readily in polar solvents. Solubility varies with ionic strength, pH, and excipient content in downstream formulation systems. For critical applications like API synthesis or analytical use, filtration through fine membranes and pH-controlled dissolution are standard practice to maintain batch consistency and minimize particulate introduction.
We define technical and pharmaceutical grades according to end-use: standard industrial lots allow wider impurity tolerances and variable particle size, while custom high-purity material follows a tighter specification envelope. Each grade shows characteristic impurity profiles—amide analogs, overalkylated derivatives, and unreacted starting amines as the principal targets for control.
Impurity thresholds are set by intended application, chemical route, and regulatory requirements. For non-pharma grades, limits reflect process capabilities and downstream tolerance; for regulated markets—limits are restrained by ICH Q3A/B or customer-defined consents. Batch impurity profiles shape subsequent process parameters—routine monitoring is tied closely to release criteria and customer qualification audits.
Purity and assay are measured by HPLC or GC. Identity tests and qualitative checks may use IR, NMR, or mass spectrometry in development and validation. All analytical procedures follow internal SOPs calibrated against certified reference standards where available. Test method selection adapts to batch history and previous deviations, not just standard protocols.
Production quality rests on raw material integrity. We require provenance and quality documentation for main feedstocks—such as racemic 2-aminobutyric acid—or relevant precursors. Supply chain checks scrutinize batch traceability and contaminant risk, particularly for regulated market supply.
Most manufacturing employs direct amidation or condensation of racemic 2-aminobutyric acid or its derivatives. Reaction control focuses on limiting side-product formation through stoichiometry, temperature, and solvent management. Catalyst or activating agents differ with process design and customer requirements, influencing both yield and cost.
Critical stages include end-point monitoring of conversion, multi-solvent crystallization, and mother liquor recirculation as sustainability considerations. Key impurities stem from incomplete conversion or excessive reagent residues, requiring careful monitoring and sometimes successive washing or recrystallization. Process adaptation occurs in response to raw material shifts or observed impurity spikes.
Quality control checkpoints span from in-process sampling to final batch analytical review. Release decisions balance product assay, impurity clearance, and consistency with historical trends. Deviations trigger root cause investigation—corrective action includes full lot quarantine or optimization of process parameters.
DL-2-Aminobutyramide acts as a building block for further amide, amine, or acyl functionalization. Amide hydrolysis, N-alkylation, and acylation represent the main downstream transformations in pharmaceutical and fine chemical pathways.
Standard reaction conditions utilize aqueous or mixed organic-aqueous media, often under controlled pH or inert gas blanket for moisture/air-sensitive intermediates. Catalysts and activators are selected for efficiency and byproduct minimization.
Main derivatives include N-alkylated and N-acylated analogs, varying by application sector. Downstream users may convert the molecule to pharmaceutical actives, intermediates, or specialty polymers.
Material storage focuses on minimizing exposure to temperature swings, humidity, and light. High-purity or pharma grades frequently see use of nitrogen-blanketed containers. Unprotected storage speeds degradation; even technical grades require sealed drums or liners.
Packaging selection considers chemical compatibility—HDPE or lined steel for bulk, specialty polymer vials for sensitive uses. Moisture ingress and oxygen permeation both risk purity loss over time.
Shelf life depends on grade, storage condition, and exposure history. Degradation generally appears through increased moisture, color shift, or new impurity peaks found during routine re-analysis. Rejection or reprocessing occurs as soon as QC flags significant deviation.
Hazard classification is tied to batch purity and intended handling scenario. Most grades carry at least an irritant warning. Detailed classification remains subject to accurate, up-to-date testing and applicable regional regulation.
Short-term exposure risk originates from inhalation of powder, dermal contact, or splashing during dissolution. Engineering and administrative controls ensure operator safety—local exhaust, gloves, eye shield, and full written procedures for open handling steps.
Acute and chronic toxicity remain grade-dependent and vary with unreacted precursor levels and process-specific byproduct content. Actual LD50 or NOAEL values are referenced against validated toxicological databases and regulatory filings.
No single workplace exposure standard fits all grades; user-site specific risk assessment defines necessary controls. Process SOPs dictate transfer method, spill clean-up, emergency response, and disposal aligned with regulatory best practices and demonstrated batch risk.
Domestic and export production volumes for DL-2-Aminobutyramide are determined by both available synthetic active ingredients and customer nomination orders. Multi-step organic synthesis often requires careful raw material scheduling, especially during periods of upstream intermediate volatility. Actual output quantities reflect reactor utilization, supply contracts, and facility usage balancing between pharmaceutical, biotech, and advanced material demand. For customer-specific grades, output aligns with qualification cycles and lot release intervals of the requesting segment.
Standard lead times for DL-2-Aminobutyramide are driven by both prior reservation of intermediates and batch campaign scheduling. Orders for non-pharma grades are generally released faster, provided stock exists from previous campaigns. MOQ aligns with reactor and isolation constraints; technical grades generally ship at kilo-lot minimum, while specialty or high-purity orders may require higher volumes for batch validation and quality assurance. Lead times extend when extra purification or analytical release is required.
Drum and HDPE container sizes correlate with required transport protection, moisture barriers, and regional regulations for hazardous or regulated chemicals. Special packaging, including liner bags or composite containers, can be specified for high purity or sensitive applications, subject to customer risk assessment protocols.
Standard shipping modes depend on the chemical classification and customer-specified Incoterms. Export is routinized through sea or air, subject to international chemical transport regulations. Payment terms typically follow established trade practice, but may shift based on credit evaluation, customer-supplier relationship, and market direction. For recurring business, favorable settlement cycles support regular production allocation.
Primary input costs for DL-2-Aminobutyramide center on base amino acid derivatives, protected intermediates, and solvent selection. Changes in the global prices of key starting materials, such as butyric intermediates, drive fluctuations. Higher purity grades intensify energy and solvent usage in final crystallization and isolation, increasing per-unit cost. Labor and batch energy draw do not scale linearly with volume—affecting small-scale specialty batches in particular.
Price volatility arises mainly from surges in demand from pharma and biotech, tighter environmental controls on precursor synthesis, and periodic shortages of hazardous route reagents. Regulatory shifts in producer countries can abruptly reroute global trade flows, affecting input availability and time-to-market for batch deliveries. The regional availability of reagents and evolving compliance criteria in developed economies create downstream price differentiation.
Grades that require either lower impurity profile or enhanced analytical data carry significantly higher production and QA cost. Technical grades typically allow more relaxed control over certain trace components, reflecting upstream material variability and less intensive batch documentation. Pharma and specialty chemical buyers routinely demand lot-specific analytical profiles, audit traceability, and certified chain-of-custody, which substantially increases documentation and release cost. Packaging certified for pharmaceutical or food-contact use drives up per-unit packaging cost, especially for export orders requiring multilayer protection and regulatory marking.
Market supply for DL-2-Aminobutyramide connects closely to the maturity of domestic synthetic routes in China, India, and select EU sites, with US and Japan driven more by imported API intermediate needs. Supply gaps typically emerge from advanced purification requirements and regulatory delays in key producing regions. End-market medical, biotech, and fine chemical manufacturers control spot demand—pushing cycle volatility in project-driven seasons.
China remains the primary source of intermediate-grade supply, leveraging access to upstream chemicals and lower manufacturing overhead. Indian producers focus increasingly on pharma and contract-grade supply, subject to ongoing regulatory audits. The US and EU base supply chain security and compliance as major purchase drivers, often favoring either domestic production or import from certified Asian suppliers. Japanese buyers pursue ultra-high-purity loads with strict documentation, limited by domestic capacity.
Ongoing regulatory tightening of precursor access and stricter environmental controls are projected to pressure production costs in Asia through 2026. Increased Western demand for analytical-grade intermediates will drive a wider gap between high and technical grades. Global price differentials will likely grow as local compliance costs build into the delivered price, especially for made-to-spec batches. Price relief could appear for non-regulated hot-run batches in factories with contract flexibility and confirmed raw material sources.
Forecasting leverages proprietary sales order and procurement data, batch cost accounting, published trade statistics, and regulatory pipeline updates. Supplier-side perspectives combine real-time sourcing intelligence with backward integration analysis and open-market tender results where available.
Notable increases in demand traced to expanding biopharma markets have prompted several producers to invest in campaign-scale upgrades and improved in-process control for impurity management. Tightening requirements for impurity profiling in US and EU markets continue to shape purification process selection.
Constant evolution in chemical registration and environmental permitting requirements impacts both existing and new product campaign schedules—especially in China and India. Upcoming changes in the EU’s REACH requirements and stricter US FDA intermediate traceability standards are key variables in global pricing trajectories.
Multi-source raw material strategies and qualifying alternative synthesis routes are now a standard hedge against regulatory and supply chain disruption. When upstream volatility spikes, flexible campaign planning and forward procurement of rare reagents insulate against downstream price jumps. Enhanced batch documentation and investment in analytical certification reinforce security for high-grade buyers facing new compliance scrutiny.
DL-2-Aminobutyramide plays a role in multiple sectors due to its intermediate character and amide reactivity. Manufacturers in pharmaceutical synthesis, fine chemicals, chiral synthesis, and agrochemical intermediates frequently integrate DL-2-Aminobutyramide into their process development. Its amine and amide functionalities make it suitable in several building block and API precursor routes. Choice of grade becomes important when moving from pilot to commercial scale, or when regulatory compliance enters the conversation—particularly in Pharma GMP, food contact, or certain high-purity biotech applications.
| Industry | Matching Grade | Key Properties & Requirements |
|---|---|---|
| Pharmaceutical Synthesis | Pharma/AnaSpec grade | Purity, trace impurities, low residual solvents, compliance to pharmacopeia or ICH-Q3 specifications where required. Release standards defined by internal QC and end-customer’s regulatory scope. |
| Agrochemical Intermediate | Technical or Industrial grade | Impurity profile, residual solvents, and moisture content matching downstream formulation requirements. Cost-performance balance often prioritized. Typically broader impurity acceptance than pharma grade. |
| Specialty Chemicals / Fine Chemicals | Fine/Specialty grade | Batch consistency, specific impurity fingerprint, solution stability. May demand tighter control over physical properties (appearance, solubility) for formulation integration. |
| Biotech or Food Contact | High Purity or Custom Qualified | Detailed traceability and stringent residual profile. Qualification on a case-by-case basis. Internal quality management adapts to meet application-specific audit requirements. |
- Purity: Final application determines necessary target—Pharma and biotech applications require higher thresholds than technical or agro grades.
- Impurity Profile: Individual customer and regulatory requests define test scope and acceptance limits. Impurities typically derive from synthesis route, raw material selection, and purification efficiency.
- Water Content: Some downstream chemistries are water-sensitive, driving specification for maximum Karl Fischer level. Lower moisture grades are prioritized for anhydrous requirements.
- Residual Solvents: Release criteria enforced more tightly where volatile by-products risk end-use contamination or regulatory setback.
- Form (Powder, Crystalline, Solution): Downstream handling and incorporation into other processes can require specific forms. Manufacturer production is capable of adjusting physical form as per technical or logistical necessity.
Clarifying end-use application stands as the starting point—pharma, agrochemical, fine chemical, or food. Each sector prioritizes different aspects of quality and performance. Early engagement with the manufacturer technical team streamlines downstream decisions.
Regulatory context shapes the grade specification. Intended submission to health authorities or market-specific registrations triggers additional data support. Pharma, food, and biotech end uses will often necessitate full traceability and higher documentation levels, warranting a different audit and batch management approach.
Manufacturing can produce baseline grades or refine further for critical applications. Requesting the impurity profile and batch data package helps align the supply with risk tolerance and process sensitivity. Certain markets or customers define their own unique specification sets, especially for impurities and elemental analysis.
Raw material selection for the synthesis, batch size, and downstream purification intensity all impact price and timeline. Lower grades may be fit for certain bulk applications, while specialty, pharma, or biotech lots involve enhanced purification, tighter in-process control, and lower yields with associated cost increases. Accurate volume forecasting improves continuity and consistency of supply.
Process integration almost always benefits from a batch sample evaluation. Manufacturers maintain traceable records for supplied samples, so unexpected compatibility issues or analytical discrepancies can be examined at the source. Validation at laboratory and pilot scale uncovers property or performance sensitivities before full adoption, supporting both technical confidence and regulatory preparedness.
Material sourcing at the manufacturer level depends on consistency of supply, trace impurity exposure, and the impact on downstream purification. Pharma and specialty routes demand higher raw material assessments, with suppliers subject to qualification and periodic re-audits.
Synthesis technology and route are chosen based on target impurity profile, throughput, and scalability. Pharmaceutical grade production pursues cleaner, more selective chemistries, minimizing process-born impurities and maximizing yield to justification thresholds. Cost-driven applications utilize routes offering acceptable impurity tolerance with volume advantage.
In-process control includes routine monitoring of pH, temperature, and key reactant concentrations. Sampling for intermediate purity tracks batch trajectory. Technical-grade product may accept broader variability than pharma or biotech grade, which require closer step-by-step monitoring.
Impurities generally trace back to raw materials, side-reactions in main synthesis, or incomplete purification. Process knowledge based on root-cause investigation supports continuous improvement to minimize these inputs, especially for high-purity or regulated markets.
Pharma and fine chemical grades use multiple-stage purification—typically involving crystallization, extractive washing, and filtration—tailored to balance cost and purity target. Technical grade streamlines this process for efficiency where minor impurities do not impact downstream usage.
Operators document and monitor each critical step through quality checkpoints. Lab analysis at each stage provides data to adjust conditions on-the-fly if deviations occur, ensuring the batch continues within defined target range. The stringency escalates with grade criticality.
Dedicated batch production logs, statistical trending of quality control results, and retained sample libraries support both customer confidence and ongoing traceability. Pharma and food-grade lots usually undergo more detailed trace analysis and hold samples for compliance audits.
Final release adheres to internal quality control criteria backed by customer specification or market-driven standards. Documentation and Certificate of Analysis are tailored to application—pharma and regulated market customers receive more granular batch data, while technical grade follows core property confirmation. Customer-defined parameters can be adopted where justified by application risk.
Production of DL-2-aminobutyramide takes place under a quality control system built around continuous risk assessment, documentation, and audit-ready transparency. Implementation of ISO-compliant quality management frameworks underpins each operational stage, reflecting regular third-party and internal audits. Change control procedures ensure that raw materials, intermediates, and packaging conform to defined supplier approval lists, and manufacturing processes align with traceable batch histories. This type of certification serves as a baseline requirement for most regulated supply chains and direct users in pharmaceutical-intermediate and fine chemicals markets.
Product release for DL-2-aminobutyramide varies by target application, with documentation tailored to customer and territorial regulatory needs. In pharmaceutical precursor applications, compliance requires evidence of current Good Manufacturing Practice (cGMP) routines, backed by validated cleaning and cross-contamination controls. For agrochemical or specialty chemical use, conformity to specific purity profiles or tox-ecotox statements becomes essential. Product batches can be accompanied by certifications such as written statements regarding compliance to REACH, ICH Q7, or other applicable statutes, conditioned by target market or region. Release conditions shift according to end-use: industrial grades emphasize batch consistency and minimal critical impurities, while research or pharma grades prioritize traceable handling and documentation trails.
Delivered product batches are accompanied by certificates of analysis (COA) and, where required, safety data sheets formatted according to GHS standards. COA content reflects actual analytical results for each lot, with reported parameters and acceptance criteria set by product grade and customer contract. Detailed impurity profiles are available for pharmaceutical-grade deliveries, with summary data retained for each batch according to the product’s assigned retention policy. Audit support files, validation protocols, and qualification summaries are shared case-by-case, subject to the nature of the customer's regulatory environment. Requests for long-form documentation—such as process validation or impurity fate studies—are managed through structured technical support protocols that align with contract confidentiality and regulatory limits.
Production scheduling for DL-2-aminobutyramide adapts to both routine order frequencies and project-based, high-volume calls. Plant campaigns are planned around forecasted demand and raw material lead times, allowing for reserved slots on contract supply as well as spot-order management. For recurring high-volume requirements, forward production agreements improve predictability and reduce lead time risk, directly supporting downstream project timelines for customers operating under seasonal or regulatory-driven launch cycles. Spot requirements can be met from campaign inventory, with volumes subject to pre-agreed allocation.
Capacity allocation for DL-2-aminobutyramide depends on the synthesis route and purification setup. Lines dedicated to high-purity batches operate with process segregation to prevent contamination, managed by batch records and routine equipment cleaning documentation. Production flexibility hinges on raw material availability, production line switchover protocols, and personnel training for process-specific handling. Monthly and quarterly site capacity reviews are conducted to align capacity with standing customer commitments and market trends, supporting stable, predictable deliveries over both contract and ad hoc schedules.
Sample provision for DL-2-aminobutyramide runs as a formal request process, usually initiated through the technical support or commercial interface. Application documentation clarifies intended use, target grade, and any special specifications concerning analytical profile, impurity reporting, or packaging. Sampling pulls from validated production lots, with traceable sampling records retained for each transaction. Technical support teams partner with customers on formulation trials or analytical method validation, streamlining early-stage cooperations and full-scale adoption.
Business cooperation can proceed under fixed-term supply contracts, just-in-time delivery frameworks, or project-based delivery windows. For long-term partnerships, shared planning horizons offer priority production slots and periodic review meetings, optimizing both demand visibility and cost predictability. Customized supply frameworks—such as consignment stock, safety inventory buffers, or expedited release protocols—can be structured according to customer risk tolerance and market volatility. For project-based supply, dedicated batch production routines reduce cross-project interference and clarify traceability, which is especially relevant for regulated industries or tech-transfer scenarios. Process-specific and grade-specific requirements factor directly into the design of each cooperation mode, with all terms backed by written commercial and quality agreements.
DL-2-Aminobutyramide occupies a growing niche in intermediate synthesis for pharmaceuticals and fine chemicals. Research efforts center on enhancing stereoselectivity and yield in asymmetric synthesis. Synthetic chemists continue to investigate the controlled production of optically pure isomers due to their influence on downstream product activity. For industrial production, optimizing impurity profiles and minimizing side-reactions during amide formation are active areas, as these impact purification load, cost structure, and suitability for regulated applications.
Several API projects have incorporated DL-2-Aminobutyramide as a building block, particularly in the development pipeline for anticonvulsants and neurotransmitter modulators. Some agrochemical and specialty polymer manufacturers have also started exploring this compound as a function-modifying additive. Development teams are evaluating compatibility with new catalytic routes to create minimal-waste processes.
Routine issues in industrial-scale synthesis include byproduct management originating from unreacted starting materials or side-chain rearrangements. Manufacturers watch for breakthrough purification technologies such as continuous crystallization and membrane-based separations to control trace amounts of specific impurities. Momentum is building for enantioselective synthetic methodologies that avoid rare or hazardous reagents, reflecting both technical constraints and evolving regulatory guidance. Improvements in automated in-line analytical control are helping to reduce batch-to-batch variability and permit rapid process adjustment when intermediate profiles shift.
Industrial-scale consumption of DL-2-Aminobutyramide is projected to increase, primarily due to expanding demand in pharmaceutical synthesis. Bulk buyers in Asia and North America have signaled growing interest, particularly for grades with well-controlled chiral purity. Segment growth will depend on the success of new therapeutic candidates and the regulatory status of finished APIs. For technical-grade applications, demand remains linked to the health of specialty chemical and materials sectors.
Technical teams expect to see further adoption of continuous process technology, reducing batch inefficiencies and allowing closer control over critical impurity levels in sensitive applications. Catalytic process routes—especially those utilizing recyclable transition metal catalysts—have started to replace legacy chemistries in several pilot facilities. These routes help lower reliance on hazardous solvents and enable better mass balance of raw materials.
Driver projects within many production groups are pushing for raw material streams derived from renewable feedstocks. Lifecycle analysis teams place increasing focus on solvent recovery, effluent management, and reduction of process energy intensity. The shift toward greener amide formation protocols, such as enzymatic conversion and water-based condensation chemistries, offers environmental and regulatory benefits, but these routes present challenges for scale-up and impurity management in bulk supply scenarios. Sustainability data is becoming a routine part of qualification packages for customers with global supply chains and explicit green procurement criteria.
Customers often require input on optimizing reaction conditions for DL-2-Aminobutyramide in custom synthesis or scale-up projects. Technical staff support these inquiries by providing data on solubility in common solvent systems, compatibility with coupling agents, and guidance around impurity control based on the grade delivered. Support is tuned to application type; pharmaceutical partners tend to focus on trace impurity risks and regulatory documentation, while specialty materials buyers seek information on blending and cross-reactivity.
Process engineers provide hands-on troubleshooting during qualification trials, with a focus on reactor charging sequence, temperature control, and in-situ monitoring of reaction endpoints. Lab teams support customers with method sharing for impurity profiling and analytical verification. For applications sensitive to input purity or trace metals, production teams arrange batch samples meeting project-specific criteria. Feedback loops with formulation customers drive continuous product adjustment—supporting surfactant compatibility, polymer blending, or downstream deprotection conditions based on application requirements.
Manufacturers commit to maintaining batch traceability and archival of quality control release data for all delivered material. In cases of quality-related complaint or non-conforming batches, technical and production liaisons respond with root-cause review, identification of supply chain or handling deviations, and prompt replacement or corrective measures according to internal policy. Post-delivery audits and support remain available for customers who encounter scale-up difficulties, unexpected reactivity, or downstream formulation shifts during their product lifecycle. Dedicated support personnel maintain knowledge of evolving regulatory and technical requirements to assist customers as market requirements shift.
DL-2-Aminobutyramide is produced in-house at our manufacturing facility using controlled synthetic processes that meet strict batch consistency benchmarks. Production runs follow standardized procedures, monitored each step through in-line controls and analytical testing. We maintain traceability on all lots, recording equipment parameters and raw material origins. Our chemists optimize conditions to target low impurity profiles and predictable particle characteristics, translating directly to plug-and-play compatibility for downstream processing and blending.
DL-2-Aminobutyramide enters a variety of formulations in specialty chemical, pharmaceutical, and fine chemical sectors. Bulk buyers in intermediate synthesis, custom API development, food technology R&D, and select polymer manufacturing have moved to this building block because of dependable performance with minimal batch variation. Repeat demand comes from sectors where batch reproducibility determines process yields and final quality grades.
Our process stability stands out due to real-time monitoring systems installed within each reactor line. We employ validated methods for purity checks, including HPLC and NMR, to verify every production lot. These methods exceed qualifying standards set by both international and local industrial guidelines. We invest in in-house calibration and staff training so that data from one shift to the next holds the same reliability customers expect from direct manufacturing origin. Retained reference samples and digital batch records enable backward investigations and continuous evaluation—yielding outcomes buyers see in year-over-year consistency.
Packaging configurations range from secure fiber drums to high-density polyethylene containers, selected for physical protection and compatibility during transport. Production and logistics interface directly, so line managers schedule finished goods delivery according to customer lead times. Our in-plant storage and outbound loading allow for staging both LTL and FCL shipments on a weekly basis. Direct control of inventory and packing reduces hold-ups common elsewhere in the supply chain. Advance storage and dispatch planning supports blanket orders and recurring bulk contracts.
Plant chemists and application specialists field direct technical queries from our industrial customer base. Consultation includes specification advice, review of analytical data, and application recommendations based on process requirements. Because formulation and scale-up often need advance input, we supply technical documentation and sample support upon qualification. By handling analysis and feedback internally, we shorten technical decision cycles and speed up project launch for both R&D and commercial users.
Working with a direct producer eliminates the handoffs and risk profiles common in intermediated supply. Manufacturing teams see benefit from certainty in specification and delivery timing. Distributors rely on documented, batch-specific analytics that back up warranty and traceability obligations to their own clients. Procurement teams access predictable lead times and transparent production scheduling, allowing sharper inventory planning and negotiation for ongoing partnerships. Direct dialogue with the production and technical staff keeps all parties aligned on evolving market needs, regulatory shifts, and efficiency targets. This approach supports more stable pricing strategies and reinforces our reputation as a single-source manufacturer committed to technical and commercial accountability.
Our production team has synthesized DL-2-Aminobutyramide for years, so we speak from experience every time customers raise questions about purity and specifications. We understand the downstream impacts that even minor impurities or inconsistent specs can create during downstream formulation, whether for pharmaceuticals, research, or advanced materials. The stakes for this compound go far beyond routine analysis. Consistency from drum to drum and batch to batch powers reliable outcomes for both R&D and manufacturing clients.
The purity of DL-2-Aminobutyramide isn’t just a number. Typical GMP requirements and research protocols often stipulate minimum levels above 98%. Across every production run, we utilize validated analytical methods—HPLC, GC, NMR, and mass spectrometry—to confirm each lot falls within this narrow purity range. We reject batches or isolate fractions that do not meet the threshold, even if the deviation is slight. This rigorous screening prevents downstream contamination and performance failures that no scientific workaround can fix after the fact.
Trace impurities pose real risks, especially for life sciences work where metabolite interference can throw off toxicology data. Our chemical analysts regularly compare current lots against reference standards, documenting each certificate of analysis down to minor byproducts. Even for applications where regulatory filings are not relevant, our partners cite fewer process interruptions and less rework on their end due to our batch-to-batch consistency.
Some customers only ask about purity, but experienced users dig into the full specification: moisture content, melting point, pH in aqueous solution, and optical rotation (for chiral centers). We maintain records for every release. For moisture, we employ Karl Fischer titration and ensure water remains below strict thresholds, as excess moisture can initiate degradation or skew solubility. Our melting point measurements help spot evidence of polymorphs or unreacted precursor. All data is traceable and year-to-year trends get reviewed during every internal audit.
Our technical team routinely tackles client-specific modifications: particle size adjustments for custom formulations or alternative packaging to maintain stability. We have handled requests for higher purity fractions, repeat analysis reports for regulatory submissions, and have even matched older legacy production specs still demanded by long-term partners. Satisfying these expectations depends entirely on controlling every step in-house. Independent laboratories can confirm what we've produced, but real authority lies in the procedures we implement at factory scale.
Producing DL-2-Aminobutyramide is not a “set and forget” exercise. We regularly invest in analytics, staff training, and process improvements. The factory monitors environmental controls at every stage—temperature, humidity, raw material qualification, and final packing. Auditable records stretch back years, offering customers full traceability. Whenever we update a production process, our QA group validates that resulting lots still meet all historical requirements before wider distribution begins. This has protected our clients from any change in yield, handling, or final usability.
We believe in full transparency around the chemical and physical characteristics of our DL-2-Aminobutyramide, and we can provide detailed specifications upon request. Commitment to clear communication, high standards, and direct oversight separates a direct manufacturer’s product from what non-producers can guarantee. Building enduring trust with every lot starts right from our lab benches and continues out to every end user.
Recent interest in DL-2-Aminobutyramide often circles around whether manufacturers maintain reliable supplies in bulk and how quickly buyers can receive large orders. As a direct producer of this compound, we share insights based on our own experience and production capacity, rather than speculation or market hearsay.
DL-2-Aminobutyramide production requires specialized know-how to ensure purity and consistent output, particularly for buyers working at pilot or industrial scale. Our facility manages all stages in-house, from precursor synthesis to quality control. This approach lets us monitor every batch, limit deviations, and achieve repeatable results for each order size.
For high-volume users, advanced planning matters. Our reactors accommodate both multi-kilogram and multi-ton production runs. In our experience, most industrial customers request lot sizes of several hundred kilograms at a time; in such cases, we schedule production on a campaign basis to keep lead times predictable. Spot availability fluctuates, but regular contractual clients benefit from priority scheduling, and we recommend this approach for industries requiring tight supply continuity.
Manufacturing timelines depend on a number of practical factors. Process time from raw material charging to final product testing and packaging typically ranges between three and five weeks for standard batches. For made-to-order bulk lots exceeding several metric tons, full cycle times can reach up to eight weeks, particularly if downstream processing—like custom particle size adjustment or specialized packaging—is required.
Our logistics team coordinates freight from our factory directly to the client’s site or international shipping hub. Clients in regions with established shipping lanes typically receive delivery within seven to 15 days after production is completed. Export paperwork, especially for regulated chemicals, sometimes adds extra days depending on destination market requirements or customs processing.
One persistent challenge in supplying DL-2-Aminobutyramide at bulk scale remains the volatility of upstream chemical markets. Sourcing high-purity starting materials sometimes stretches procurement lead times, especially during periods of feedstock shortages or regulatory disruption. Staying transparent with forecasted delivery timelines, we collaborate closely with established suppliers and keep buffer stock of main precursors to smooth out such variances.
To address unexpected surges in demand, we invest in flexible scheduling systems, allowing rapid adjustment of campaign order. For buyers with fixed annual requirements, we structure production agreements that lock in both capacity and price for the agreed period. This strategy removes supply uncertainties and enables buyers to plan their manufacturing schedules with confidence.
Our QA/QC laboratory supports every stage of production for DL-2-Aminobutyramide, issuing full analytical reports with each lot. Technical teams handle specific customer inquiries about impurity profiles, analytical methods, and downstream application needs. Our ISO-aligned quality system ensures every shipment matches the agreed-upon specifications.
Direct-from-manufacturer transactions allow the greatest control over both product consistency and lead time management. We encourage early engagement for high-volume or custom orders, which allows us to include detailed customer requirements directly into production planning. Our track record in reliably supplying DL-2-Aminobutyramide demonstrates the value of working directly with a dedicated manufacturing partner, not an intermediary chain.
From our production floor to the shipping department, regulatory compliance shapes each step of how we manufacture and deliver DL-2-Aminobutyramide. Before we authorize a shipment of this compound, our regulatory team studies regional import and export lists, including controlled substances schedules and dual-use regulations. US, European, and Asian markets maintain their own chemical control protocols. In our experience, DL-2-Aminobutyramide does not appear on the most common controlled precursor lists, but customs officers in some jurisdictions have required chemical descriptions or proof of intended end-use. We keep up-to-date export documentation and labeling procedures for all outgoing shipments, ensuring smooth customs clearances.
Our documentation package includes certificates of analysis, certificates of origin, and shipping invoices with detailed product descriptions and Harmonized System (HS) codes. As the direct manufacturer, we certify product purity and grade directly from our quality control laboratory. We deliver Safety Data Sheets (SDS) for every batch, meeting both local and international transport safety laws. This paperwork provides customs and regulatory bodies with the traceability they request during audits or inspections.
During transport, we package DL-2-Aminobutyramide according to international standards for chemical stability and worker safety. Our typical shipment uses fiberboard drums with polyethylene liners or high-density polyethylene containers, chosen for leak prevention and ease of handling. Every unit leaves our plant sealed and labeled with all required hazard symbols and UN recommendations when applicable. Our logistics team respects temperature and humidity limits outlined by our own stability studies, minimizing degradation risk.
We train our staff and logistics partners on chemical handling procedures before each consignment leaves the warehouse. This includes spill response, secondary containment, and secure transit planning for both air and sea routes. We verify that our couriers comply with International Air Transport Association (IATA) and International Maritime Dangerous Goods (IMDG) regulations, even if DL-2-Aminobutyramide is not classified as hazardous according to GHS guidelines.
We understand that border controls evolve frequently, especially when scientific or commercial use of new substances rises. Our global trading partners sometimes report additional document requests specific to chemical nomenclature or intended application. We prepare commercial invoices listing both systematic and common names, Chemical Abstracts Service (CAS) numbers, and detailed product identification to facilitate customs processing. In several countries, customs authorities may require detailed product statements, which we provide upon request. Our technical team remains available for clarification on chemical properties or end-use requirements to government agencies to preempt unnecessary delays.
Regulatory changes remain one of the most dynamic aspects of our business. We invest significant resources in ongoing training, monitoring of compliance news, and membership in industry associations. These commitments help us foresee policy shifts before they interrupt the supply chain. As a result, our export compliance process delivers a package ready for inspection, with supporting documentation that satisfies demands set by most government authorities.
Every shipment reflects our experience as chemical producers serving diverse international markets. With our practice-based approach, we help our partners import and export DL-2-Aminobutyramide efficiently, safely, and with full transparency regarding legal and technical requirements.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
